The Dispersome® technology allows formulation of poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.
Our Dispersome® platform is based around a class of novel excipients to formulate poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.
By increasing solubility and dissolution rate the Dispersome® platform aims at improving bioavailability, therapeutic outcomes and convenience for patients.
Dispersome® formulations are compatible with standard solid oral dosage form manufacturing processes and facilities.
Zerion is a pharmaceutical development company improving the formulation of poorly soluble drugs (oral solid dosage forms) that are currently not reaching their therapeutic potential. Through the use of our proprietary formulation platform, Dispersome®, we aim to develop new treatment options for patients across all therapeutic areas.
Learn moreUp to 90 % of all new drug molecules are poorly soluble, which can be a problem as the drug must dissolve in order to be absorbed and reach its pharmacological target.
24 November, 2021 (COPENHAGEN, Denmark). Rousselot B.V. and Zerion Pharma ApS announce today that they have strengthened their partnership through an extension of
(Copenhagen, May 10, 2021). ZERION Pharma, a Danish pharmaceutical company, elected two new members Dr. Torsten Goesch and Dr. Lars Lykke Thomsen to join its board of directors at the annual general meeting held...
An international and very diverse team is behind Zerion Pharma – a drug development company improving the formulation of poorly soluble drugs that are currently not reaching their therapeutical potential...
